In a report issued on August 1, Yun Zhong from BTIG maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $35.00. The company's shares closed last Tuesday at $10.34. According to TipRanks.com, Zhong 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.6% and a 31.1% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Applied Genetic Technologies, and Mereo Biopharma Group Plc. Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $35.20, representing a 260.3% upside.
https://www.tipranks.com/news/blurbs/anavex-life-sciences-avxl-receives-a-buy-from-btig?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Anavex Life Sciences Charts.